3386
COSMO BIO COMPANY, LIMITED
コスモ・バイオ株式会社Cosmo Bio Company,Limited, together with its subsidiaries, operates as a life science trading company worldwide. It is involved in the import, export, manufacture, marketing, sales, and customer support of life science research bio tools, such as reagents, kits, instruments, and software. The company also distributes antibodies, antigens, biologically active substances, enzymes, substrates, peptides, amino acids, chemicals, carbohydrates, lipids, virus components, and bacteria, as well as detection reagents, cell and tissue culture systems, and gene analysis systems; and research instruments, including electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. In addition, it provides drug discovery and custom research services; clinical diagnostics; cell and DNA, and protein engineering solutions; disposable items and general labware; and bioactive substances; consigned services, such as intestinal flora analysis, tear fluid analysis, and cell assays services; and custom peptide synthesis and antibody production services. Further, the company manufactures and sells cell/cell culture products comprising adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, mesenchymal stem cells, feeder cells, tumor cell lines, macrophage-related, and coating reagents; measurement and staining kits, detection/purification kits related to neurodementia, macrophage/immune, exosome, and anti-saccharification/anti-aging; and biotechnology research equipment, such as constant-temperature transport containers, aluminum block mat heat insulation devices, and dew condensation prevention glass plate. It serves universities, public research institutes, and companies engaged in biological science. Cosmo Bio Company, Limited was founded in 1978 and is headquartered in Koto, Japan.
Price
¥1,232
Market Cap
¥7.0B
Ent. Value
¥4.3B
Net Cash
¥2.7B
Shares Out.
5.7M
P / E
20.8×
EV / EBIT
12.4×
P / Book
0.75×
P / NCAV
1.48×
Div. Yield
4.06%
Financials
| Metric |
FY 2025
EDINET ↗ |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| Net Sales | ¥10.8B | ¥10.0B | ¥9.3B | ¥9.6B | ¥9.2B |
| Cost of Sales | ¥7.1B | ¥6.7B | ¥6.1B | ¥6.1B | ¥5.6B |
| Gross Profit | ¥3.7B | ¥3.3B | ¥3.2B | ¥3.4B | ¥3.7B |
| SG&A | ¥3.4B | ¥3.0B | ¥2.7B | ¥2.6B | ¥2.6B |
| Operating Income | ¥343M | ¥318M | ¥519M | ¥816M | ¥1.0B |
| Non-Operating Income | ¥158M | ¥86M | ¥136M | ¥57M | ¥71M |
| Dividend Income | ¥88M | ¥66M | ¥50M | ¥41M | ¥37M |
| Interest Income | ¥6M | ¥0M | ¥0M | ¥0M | ¥0M |
| Non-Operating Expenses | ¥12M | ¥40M | ¥2M | ¥83M | ¥20M |
| Interest Expense | ¥0M | ¥0M | ¥0M | ¥0M | ¥0M |
| Ordinary Income | ¥489M | ¥364M | ¥653M | ¥790M | ¥1.1B |
| Pre-tax Income | ¥504M | ¥369M | ¥653M | ¥790M | ¥1.1B |
| Income Taxes | ¥170M | ¥99M | ¥191M | ¥238M | ¥330M |
| Current Tax | ¥202M | ¥120M | ¥215M | ¥241M | ¥346M |
| Deferred Tax | ¥-32M | ¥-20M | ¥-23M | ¥-3M | ¥-15M |
| Net Income (owners) | ¥337M | ¥262M | ¥442M | ¥517M | ¥737M |
| Minority Interest | ¥-3M | ¥7M | ¥19M | ¥35M | ¥31M |
| Comprehensive Income | ¥810M | ¥826M | ¥585M | ¥508M | ¥848M |
| EBITDA | ¥510M | ¥454M | ¥667M | ¥957M | ¥1.2B |
| EPS | ¥59.26 | ¥45.05 | ¥75.97 | ¥89.13 | ¥126.94 |
| Shares Outstanding | 5.7M | 5.7M | 5.8M | 5.8M | 5.8M |
| Shares Issued (total) | 6.0M | 6.0M | 6.0M | 6.0M | 6.0M |
| Treasury Shares | 0.4M | 0.3M | 0.2M | 0.2M | 0.3M |